Products & Services

iCell® Cardiomyocytes Genetic Diversity Panel

Investigate Pharmacological Response across a Cohort of Healthy Donors In Vitro

Description
Product Highlights
Performance Data
Protocols
Description

High attrition rates represent a major pitfall for the pharmaceutical industry because current preclinical models do not sufficiently predict drug effects in humans. Critical to these failures are inter-individual variability to drugs. This variability creates a significant need to develop more predictive in vitro models that enable investigation of into inter-individual response. This is ideal for both both safety and efficacy studies within drug development to identify cardiotoxicity early and avoid failures in the clinic.

 

To enable researchers to evaluate how compounds affect individuals differently and gain more confidence in their findings, FCDI has created the iCell® Cardiomyocytes Genetic Diversity Panel. This reliable, predictive model provides a new solution for more predictive safety and toxicity assessment.

 

Best-in-Class Biology

FCDI’s iCell Cardiomyocytes Genetic Diversity Panel are derived from apparently healthy, normal individuals with no known disease-related genotypes. These cardiomyocytes exhibit the relevant biology, diversity, and functionality to advance research and preclinical studies for cardiotoxicity and cardio-oncology.

 

  • ●  Fully differentiated, >90% pure cardiomyocytes
  • ●  Expression of relevant cardiac markers (e.g. cTNT, ACTN2)
  • ●  Reproducible biology

 

All lines in the iCell Cardiomyocytes Genetic Diversity Panel are provided with:

  • ●  Cryopreserved iCell Cardiomyocytes
  • ●  30 ml iCell Cardiomyocytes Plating Medium
  • ●  100 ml iCell Cardiomyocytes Maintenance Medium
Product Highlights

Figure 1: iCell Cardiomyocytes Genetic Diversity Panel
FCDI generated human iPSCs from a panel of apparently healthy, normal individuals and then differentiated to cardiomyocytes. This panel was highlighted in Grimm et al., 2018.


Figure 2: Panel Demographic
The donor backgrounds of the iCell Cardiomyocytes Genetic Diversity Panel correspond closely to the distribution within the United States.

Performance Data

Figure 3: Preclinical Trial in a Dish Using a Subset of the Larger Cohort
A smaller cohort can be selected to better understand pharmacological response in a specific population.


Figure 4: Real Life Case Study
Panel A shows representative calcium traces from 6 donors from the in vitro cohort, baseline, and pharmacological response to isoproterenol, propranolol, and cisapride. Panel B shows concentration-response curves from a larger cohort of 27 donors for isoproterenol, propranolol, and cisapride. Data were modified from Grimm et al., 2018.


Figure 5: Assessment of Type I and Type II Cancer Therapeutics-related Cardiac Dysfunction (CTRCD)
Panel A shows cell index (i.e. viability) traces from 6 donors from the in vitro cohort exposed to doxorubicin Type I CTRCD at three concentrations 0.1, 1.0, and 10 µM. Panel B shows cell index (i.e. viability) traces from 6 donors from the in vitro cohort exposed to Sunitinib Type II CTRCD at three concentrations 0.1, 1.0, and 10 µM (ACEA Biosciences). Type I CTRCD may be associated with cellular death, structural changes, and permanent damage while Type II CTRCD may be associated with cellular dysfunction, no structural changes, and reversible damage. These data suggest that researchers can gain valuable information regarding Type I vs Type II CTRCD across multiple donors with regard to cell index (i.e. variability) from using a selected cohort from the iCell Cardiomyocytes Genetic Diversity Panel. Additional insight into sensitivities to cancer therapeutics can be assessed as some donors are more or less sensitive than others (A, middle panel).

Protocols

Protocols

Application protocols for iCell Cardiomyocytes have been optimized for cells derived from the genetic background 01434. A subset of these protocols have been tested with cells derived from the genetic background 11713 and require no modification. Additional applications have not yet been tested using other lines within the panel. Protocols supported for both iCell Cardiomyocytes, 01434 and 11713:

 

Full List of Application Protocols

User Documentation